Dear Editor,
Glutaminase catalyzes the first step of glutamine metabolism, converting glutamine to glutamate, which enters the tricarboxylic acid cycle. In human, glutaminase is encoded by two different genes, GLS1 and GLS2.1 GLS1 can be alternatively spliced into kidney glutaminase A (KGA) and highly active glutaminase isoform C (GAC)1 (Fig. 1a). GAC can be further activated by anions.2 It has been observed that GAC can form active filaments both in vitro and in vivo.3,4 Glutamine, in addition to glucose, is another vital metabolite for cell.5,6 Glutaminase, especially the GAC isoform, is highly overexpressed in various cancers for the utilization of glutamine.7,8 Currently, a specific glutaminase inhibitor is undergoing several clinical trials.9,10 Activating glutaminase can effectively eliminate cancer cells and solid tumors, and has significant therapeutic potentials.11
In 1947, it was discovered that phosphate (Pi) could significantly enhance the activity of glutaminase.2 To obtain a structural basis for this, GAC protein was expressed (Supplementary information, Fig. S1). The addition of Pi can stimulate both the enzymatic activity (Fig. 1b) and the filamentation of GAC (Fig. 1c, d; Supplementary information, Fig. S2). Cryo-EM samples of GAC containing Pi and an analog of glutamine, 6-Diazo-5-oxo-L-norleucine (DON) were prepared. We resolved the structure of GAC filament at a resolution of 2.9 Å (Supplementary information, Figs. S3, S4 and Table S1). GAC forms filaments with tetramers as the helical unit (Fig. 1e). By viewing the filament from the top, the twist angle of ~51° can be observed (Fig. 1f).
The helical assembly interface is composed of four protomers. The secondary structures involved in the assembly interface are α-helices 351–365, 375–384, 407–419 and β-barrel 371–373 (Fig. 1g). Sequence alignment shows that the amino acids involved in the helical interface, F355, F373, N375, F378, Q379, and Q416, are highly conserved in mammalian glutaminase (Supplementary information, Fig. S5). A GAC tetramer contains four Pi binding sites, which are located on the dimer–dimer interface, consisting of R317 and K320 on the activation loop (AL), as well as R387, Y394′ and K398′ on the dimer–dimer interface (Fig. 1h, i). Sequence alignment reveals that these amino acids are highly conserved in mammalian glutaminase (Supplementary information, Fig. S5). The Pi binding site contains multiple positively-charged amino acids. This structural feature provides a basis for the requirement of multivalent acids to fully activate GAC (Fig. 1i).
To investigate the functional significance of GAC filamentation and its relationship with Pi, we designed point mutations disrupting the filamentation interface of GAC (Supplementary information, Fig. S6a). Negative-stain electron microscopy (EM) revealed that Q416A disrupted the filamentation of GAC (Supplementary information, Fig. S6b). We then performed activity assays on Q416A. In the Apo state and the Pi bound state, the activities of Q416A are 0.26 times and 0.63 times of those of the wild-type GAC, respectively (Fig. 1j). Significant conformational changes were observed in the GAC tetramer bound with Pi when comparing the tetramers in filament to free tetramers, and the RMSD between them is greater than 2 Å. To avoid confusion, we will use the term “GAC-PF tetramer” to refer specifically to the filamentous GAC tetramer bound with Pi.
First, the GAC-PF tetramer changes into a compressed form, with each protomer rotating by 5.6° (Fig. 1k). Second, the AL (residues 308–334) of each protomer in the GAC-PF tetramer is reshaped and stabilized (Fig. 1l). The AL is a dynamic long loop involved in glutaminase reaction, being absent in most GAC structures (Supplementary information, Fig. S7). However, in the GAC-PF tetramer, the B-factor analysis of our models shows that the AL is in a stable state (Supplementary information, Fig. S8). Compared to DON-inhibited glutaminase tetramer and the dimer formed by disrupting the dimer–dimer interface (PDB codes: 4O7D and 5W2J), the AL of GAC-PF tetramer exhibits a closed conformation towards catalytic core, with the loop of 316–322 moving inward by ~2 Å (Supplementary information, Fig. S9a).
The closed AL alters the catalytic pocket of GAC (Fig. 1l). First, the stabilized AL further fills the catalytic pocket (Supplementary information, Fig. S9b, c). Second, the π–π interaction between F318 and Y466 changes the position of the Y466 loop, reducing the steric hindrance between Y466 and F318 and increasing the affinity of the catalytic pocket. This explains the decrease in enzyme activity caused by F318A reported by Sivaraman group in 2012.12 Finally, the downward movement of Y466, N335 and AL also reshapes the catalytic pocket (Fig. 1l). As revealed by the previous study, Y414 and Y466 act as proton transferors, while K289 acts as a proton donor (Supplementary information, Fig. S10). In the remodeled catalytic pocket, Y466, K289, and Y414 are located on the same plane, and the distance between Y466 and K289 is close, which could facilitate proton transfer and product release, thereby accelerating the reaction (Supplementary information, Fig. S9d).
CB-839 (Telaglenastat)10 and BPTES13 are non-competitive inhibitors targeting GLS1. Although both BPTES and CB-839 have fascinating specificity and anti-tumor activity, the lack of investigation of an accurate activation mechanism has, to some extent, limited our understanding of them. We aimed to examine the impact of inhibitors on GAC filament formation by adding inhibitors to pre-existing filament samples. Initially, GAC was incubated at 37 °C in a 40 mM phosphate system for 10 min, resulting in the formation of GAC filaments in the system. Upon the addition of both inhibitors, they demonstrated varying degrees of efficacy in disrupting the formation of the filaments and converting filamentous GAC tetramers into free tetramers (Supplementary information, Fig. S11a). Our quantitative analysis revealed that BPTES significantly reduced the abundance of GAC filaments and shortened the length of each filament. In contrast, CB-839 exhibited stronger ability in disassembling GAC filament and no filament was observed in the quantitatively counted images (Supplementary information, Fig. S11b, c).
The conformational changes of the tetramer explain the effect of inhibitors on GAC filament formation (Fig. 1m; Supplementary information, S12a). When BPTES or CB-839 bound to GAC, the AL interacted with inhibitors, making the outward rotation of the GAC catalytic core and the inward shrinkage of the N-termini, as compared to the GAC-PF tetramer.13 The inhibited tetramer exhibited a mode of expansion hindering the glutaminase filamentation. Glutaminase activity experiments conducted simultaneously with negative-stain EM demonstrated varying degrees of inhibition of GAC activity by BPTES and CB-839. Specifically, at a concentration of 0.9 μM, BPTES exhibited significant inhibition of GAC activity, while CB-839 almost completely inhibited GAC activity (Supplementary information, Fig. S11d).
Comparing GAC-PF tetramer with inhibitor-bound tetramer, we find that the natural activator Pi and inhibitors are antagonistic competitive ligands of GAC. On the one hand, both Pi and inhibitors bind to the dimer–dimer interface. When two tetramers are aligned, the binding of inhibitors and Pi overlaps with each other; thus the binding of inhibitors would create steric hindrance and directly limit Pi binding and GAC activation (Fig. 1n; Supplementary information, S12b). The overlap of the binding sites also suggests that Pi and inhibitors cannot co-exist in GAC. On the other hand, compared to the ordered fixation of the AL by Pi, inhibitor binding fixes the AL in a different mode, keeping it away from the catalytic active site and making the catalytic reaction less likely to occur (Fig. 1n; Supplementary information, S12b).
In this study, utilizing cryo-EM and available structures, we determine the binding site of Pi and propose a mode and mechanism of GAC activity regulation by different ligands and GAC filamentation (Fig. 1o). In the GAC-Pi tetramer, the AL is disordered, and the catalytic pocket is wide open. However, when Pi-bound GAC forms a filament, the AL is stabilized, and the pocket is remodeled, resulting in highly active GAC. When the antagonist CB-839 binds to GAC, the AL is fixed away from the pocket, resulting in a wide-open pocket and inhibition of GAC (Fig. 1p).
Our work provides the long-sought activation mechanism of glutaminase, and significantly advances our understanding of the inhibition mechanism and filamentation of glutaminase.
Data availability
The structure data are available under EMD accession codes EMD-35573 and EMD-35574, and PDB codes 8IMA and 8IMB.
References
Elgadi, K. M., Meguid, R. A., Qian, M., Souba, W. W. & Abcouwer, S. F. Physiol. Genomics 1, 51–62 (1999).
Carter, C. E. & Greenstein, J. P. J. Natl. Cancer Inst. 7, 433–436 (1947).
Olsen, B. R., Svenneby, G., Kvamme, E., Tveit, B. & Eskeland, T. J. Mol. Biol. 52, 239–245 (1970).
Ferreira, A. P. S. et al. J. Biol. Chem. 288, 28009–28020 (2013).
DeBerardinis, R. J. et al. Proc. Natl. Acad. Sci. USA 104, 19345–19350 (2007).
DeBerardinis, R. J. & Cheng, T. Oncogene 29, 313–324 (2010).
Turner, A. & McGivan, J. D. Biochem. J. 370, 403–408 (2003).
Zacharias, D. P. et al. Cell Biochem. Funct. 21, 81–84 (2003).
Bajor, D. https://clinicaltrials.gov/study/NCT02861300 (2016).
Gross, M. I. et al. Mol. Cancer Ther. 13, 890–901 (2014).
Jiang, B. et al. Mol. Cell 82, 1821–1835.e6 (2022).
Thangavelu, K. et al. Proc. Natl. Acad. Sci. USA 109, 7705–7710 (2012).
DeLaBarre, B. et al. Biochemistry 50, 10764–10770 (2011).
Acknowledgements
We thank Suwen Zhao for her helpful discussions. EM data were collected at the ShanghaiTech Cryo-EM Imaging Facility. We thank the Molecular and Cell Biology Core Facility at the School of Life Science and Technology, ShanghaiTech University and Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine for providing technical support. This work was supported by the Ministry of Science and Technology of China (2021YFA0804700), the National Natural Science Foundation of China (31771490), Shanghai Science and Technology Commission (20JC1410500), UK Medical Research Council (MC_UU_12021/3 and MC_U137788471) to J.L.L.
Author information
Authors and Affiliations
Contributions
C.J.G. and J.L.L. conceived and supervised the study. C.J.G. and Z.X.W. performed the experiments. C.J.G. drafted the manuscript. C.J.G., Z.X.W. and J.L.L. reviewed and edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Guo, CJ., Wang, ZX. & Liu, JL. Structural basis for activation and filamentation of glutaminase. Cell Res 34, 76–79 (2024). https://doi.org/10.1038/s41422-023-00886-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41422-023-00886-0